Race,* as opposed to ethnicity, is a predictor of questionable value for differences in susceptibility to, and pathogenesis of, disease susceptibility. As social constructs, however, both race and ethnicity are powerful organizing forces employed both by those who use differences to stigmatize and those who view differences as a source of pride, community, and shared history. Even as society acknowledges that humans are more alike than different, efforts to eliminate race in medical research are met with as much suspicion as those attempts to employ race in research design. In some instances, the opposition to abandon racial categories has come from those groups who have historically suffered poor treatment or stigma based on race. History has bred distrust among historically disfavored population groups of the possible agendas of those who would now abandon racial categories as a marker or measuring stick for any purpose.
In the age of genomic research, a debate has arisen over the proper role, if any, of such social categories as race and ethnicity in medical research. The conflict over the role of race in medical research is particularly acute in the context of biomedicine. Race and eth-*For purposes of this discussion, the term 'race' is defined as 'a distinct ethnic group characterized by traits that are transmitted through their offspring'. An ethnic group is 'a social group or category of the population that, in a larger society, is set apart and bound together by common ties of race, language, nationality or culture'. Census, Race and Science. Nat Genet 2000; 24: 97-98.
nicity have long been used in medical research and clinical medicine. The use of both concepts reflects traditions of shared experience borne of discrimination based on physical differences like skin color. Such discrimination contributed to the development of cultures based on shared geographic environments and social obstacles to intermarriage. Advances in genetic research have demonstrated that biological heterogeneity within ethnic groups makes race a particularly poor predictor of disease susceptibility and treatment. 2 One side of the debate consists of those who insist on the immediate elimination of the use of race in medical research and clinical medicine. This argument emphasizes what we now know to be the extent to which we are all genetically very much alike and the tiny extent to which we differ from one another. Attempts to study or use race as an identifier are interpreted as an effort to preserve race as a biological fallacy or to encourage an overemphasis of either the differences between any two persons or the similarities between persons.
On the other side are those who point to evidence of difference between ethnic communities that is relevant to health status or disease susceptibility. Apart from disease susceptibility, 3 scientists have observed that a number of genetic polymorphisms that affect drug metabolism occur with varying frequencies in different ethnic communities around the world. Without denying the extent to which all humans are genetically similar, some argue that the abandonment of race would unnecessarily discount what value may remain in its use in the study of genetic variation among populations.
The appropriate position on the issue probably falls between these two positions. The challenge to resist racial bias is proper and logical, given the irrefutable harm caused by centuries of misguided science based in part on race. To suggest that the study of the significance of genetic variations between people offers nothing of value, however, may represent an immaturity or lack of depth necessary to fully exploit the promise of genetic research. Race is a social invention rather than a biological reality. Those who use race in medical research and clinical practice must re-evaluate the standards or criteria for its use. At least one study has called for an emphasis on ethnicity over race in scientific dialogue. 4 Ethnicity is a more flexible concept that connotes more in the way of shared experience and relatively less of biological or visible physical traits. Rather than continue to rely on vague notions of race and ethnicity, researchers and lay persons alike must be pressed to define precisely the meaning intended through the use of such politically loaded terms.
Advances in pharmacogenetics demonstrate the suggestion that, from the biomedical perspective, genetic research is valuable and important for what it reveals about human variation rather than human sameness. 5 Pharmacogenetics is the study of inherited genetic influences on drug response. By understanding which genetic factors are particularly relevant to the success or failure of a particular drug therapy, researchers and manufacturers hope to provide better drugs designed to benefit persons of a particular genotype. ‡ Pharmacogenomics ‡Ultimately, the aim of pharmacogenomics is to enable physicians to tailor drug therapy to the individual based on that individual's genotype.
expands beyond pharmacogenetics to include genomic variations in drug target genes or gene expression differences in health and disease states. New technologies such as high throughput screening and computational biology have facilitated the rapid genotyping of many genomes necessary to achieve the comprehensive representation of diverse groupings of human populations and the different relevant polymorphisms. 7 Future use of drug therapy in clinical medicine will depend not on such imprecise indicators as race or ethnicity, but on the individual patient's genotype. The idea, then, is not to eradicate or ignore differences but to redefine or move beyond race to more precise categories of difference with justification for establishing such differences. Newer, more precise categories will not be immune to such social forces as discrimination and stigma. Rather, pharmacogenetics is but one segment of genetic research that promises to change the traditional (erroneous) concept of race as a meaningful biological indicator.
The purpose of this article is to consider the use of race and ethnicity in pharmacogenomics research, particularly in the selection of subjects for research and the integration of pharmacogenomic-based drugs into clinical practice. Advances in genetic research are changing the very meaning of race and ethnicity in society. By evaluating the role of ethnicity in the specific context of pharmacogenomics, the authors hope to inform the debate over the relevance of concepts of race and ethnicity in biomedicine and perhaps elevate the standards for discussion. The second section presents a brief review of the role of race and ethnicity in the history of pharmacogenetics. The third section is a description of the ways in which race and ethnicity appear as factors in current medical research and drug development within pharmacogenomics. The fourth section is an attempt to synthesize conclusions that may contribute to a framework for future practice. Given the value in human diversity for genetic research and pharmacogenomics in particular, the use of ethnicity can not be abandoned as yet because www.nature.com/tpj ethnicity may inform efforts to identify genetic variations relevant to drug response. Rather, ethnicity should be distinguished from race, which has grown increasingly obsolete. Increased human mobility and the removal of barriers to reproduction across historical racial categories will continue to diminish the value of race as a predictor over time yet, at present, the remnants of past patterns of human migration are too important to pharmacogenomic research to completely disregard.
THE ROLE OF RACE AND ETHNICITY IN THE HISTORY OF PHARMACOGENETICS
Current drug therapy is based on the knowledge that individuals vary in how they respond to the same dose of a single drug. Physicians currently employ a trial-and-error strategy in prescribing drug therapy. Pharmacogenomics is the study of how inherited genetic variations affect an individual's ability to respond to a drug and the use of that knowledge in drug discovery and development. The presence of certain patterns in genetic composition can explain why one person may benefit from a drug while another may suffer toxic effects from the same dosage of the same drug. Researchers have identified genetic variations or genetic polymorphisms in alleles of a gene that produce either a higher or a lower expression of proteins associated with drug absorption. Computational biology tools and improvement in molecular biology will benefit the way researchers predict gene function and pharmacology. 8 Pharmacogenetics arose in the 1950s. Early studies of human variations in drug response revealed a difference in the frequency of heritable enzyme variants that were linked to drug sensitivity. 9 A deficiency of G6PD explained the destruction of red blood cells associated with the administration of antimalarial drugs in a large proportion of African-Americans, African, and Mediterranean populations. Genetically slow acetylators of isoniazid, once commonly used to treat tuberculosis, comprise almost half of the Caucasian populations studied and more than four-fifths of certain Middle Eastern populations, but fewer than one-fifth of Asians living in Japan.
Other studies noted differences in drug response that seemed to correlate with race. For example, variant forms of the enzymes that metabolize ethanol and acetaldehyde explained a difference in sensitivity to alcohol between studied persons of Japanese ancestry and Caucasians. 9 
RACE AND ETHNICITY AND CURRENT MEDICAL RESEARCH
Researchers continue to identify pharmacologically significant genetic variations that vary in frequency in different ethnic groups, or groups of persons that correspond to historical racial classifications. CYP2D6, the cytochrome P-450 enzyme responsible for the metabolism of codeine, certain antidepressants and beta-blockers, is functionally absent in 8% of Caucasians but fewer than 1% of Asians, resulting in different drug concentrations and responses in these racial groups. 9 A comparison of sulfotransferase (SULT) enzymes, which catalyze the sulfate conjugation of drugs, in different populations reveals that a group of persons with Chinese ancestry had lower frequencies of the less common alleles. 10 An AfricanAmerican group in the same study exhibited the highest frequencies of the variant alleles.
Many of the genetic variations that are predictive of drug response occur in varying frequencies in different ethnic groups. Variations in drug response are based on different distributions of polymorphisms in drug receptors or drug metabolizing enzymes among different population groups. 11 For example, the polymorphism of thiopurine methyltransferase (TPMT) catalyzes the S-methylation of several thiopurine agents used for a range of medical indications like childhood leukemia and rheumatoid arthritis. TPMT activity is variable in large populations and inherited. The frequency of mutant TPMT alleles differs among various ethnic populations. 12 The frequency of the C3435T mutation in exon 26 is sufficiently influenced by ethnicity to suggest therapeutic implications for use of Pglycoprotein dependent drugs in persons of African origin, for example. 13 The differing frequency of the occurrence of polymorphisms in different populations is relevant and meaningful to continued progress in pharmacogenomics. The completion of two drafts of the human genome represented the genome of a 'composite' human. 14, 15 The collective value of these drafts is beyond question, but efforts to integrate inherited genetic difference in drug response require a broader scope of genetic diversity. To the extent that humans are genetically diverse in meaningful ways, efforts must be made to capture such diversity in ways that are feasible or practical. Short of recording the genetic profile of every person on the planet, researchers in the public and private sectors have undertaken to develop databases containing the genomic material of participants. 16 Within the context of pharmacogenomics, the idea is to make available through sale, trade, donation, or agreement the records of the genotypes of populations that exhibit or express a polymorphism relevant to scientific inquiry, including drug discovery and development.
Documentation of the differing prevalence of certain polymorphisms in different ethnic groups does not mean that race is the best predictor of individual phenotypes or genotypes. Only 10-20% of that human genetic diversity stems from populations rather than individuals. 17 Ethnic differences in drug response are explained by shared environments and the pathogenesis of disease rather than absolute biological differences. The prevalence of diseases with a genetic basis varies among different populations. One trend in research design is to emphasize genotype above phenotype and outdated concepts of race. 18 In theory, researchers should respond to observations about individuals without regard to ethnicity and look only to the variables that may be vaguely suggested by other shared characteristics of ethnic groups. Practice may prove more difficult, how-
The Pharmacogenomics Journal ever. There is a difference between associating ethnicity with a causal relationship and noting observations in successes or failures in drug treatment that happen to manifest in groups of similar ancestry. The proper response may be to accept superficial observations as the basis for hypotheses that may lead to more information about the genetic explanation, if any, for the initial observation. Without prior information about individual genetic profiles, it is difficult and perhaps disingenuous to ignore the role of ethnicity in the formation of the hypothesis.
Drug Development and Subject Selection
One area of contradiction regarding the role of race in scientific research involves the recruitment and selection of subjects or participants in clinical drug trials. Research involving human subjects is an area of ongoing ethical debate, including the perception that the current system of protections may not be evolving with the growing complexity of issues presented by contemporary research. 19 Concerns about the loss of privacy and fear of misuse of information underlie arguments that genetic research on humans presents special issues. Research involving genetic information presents ethical concerns regarding the privacy of information not only about research subjects but also about biological relatives who may not have agreed to participate in research. 19 Regulations governing the use of human subjects in federally funded research include statements encouraging racial diversity in the recruitment of subjects for research. 20, 21 Generally, researchers are required to include women and members of racial and ethnic minority groups in research projects involving human subjects in the absence of a compelling rationale to the contrary. These policies reflect a need to abandon the use of homogeneous subject groups where sameness is not dictated by science. On another level, the policy reflects the power of race as an organizing force in society and as a variable that ensures the inclusion of all social and political units that were once systematically excluded on the basis of race. The policy of inclusion does not reflect a belief that races are biologically distinct by definition, but instead demonstrates a respect for the potential value in revealing and accommodating what differences may arise.
Guidelines that encourage inclusivity through racial diversity validate the continued use of racial classifications. 22 The selection of participants in clinical drug trials must allay the suspicions of groups who have been neglected or singled out for injurious treatment in the past. In the United States, the more infamous instances of such mistreatment have been based on race or perceptions of race. Perhaps the legacy of racism is inextricable from the political environment in which research and scientific inquiry must operate. If the reliance upon racial categories retains some value for public education about legitimate health risks or the successful diagnosis and treatment of disease, the reliance must be shifted to a more accurate and effective vocabulary for communication of complex concepts to avoid the danger of perpetuating harmful and inaccurate stereotypes.
Clinical Integration of Pharmacogenomic Medicine
The clinical integration of drugs developed through pharmacogenomic drug development technologies is important to ascertaining whether and to what extent race will persist as a variable in medical care. Reports of racial disparities in medical care in the United States are common. 23 The United States government has targeted the elimination of racial disparities in health status as a national priority in health policy. 24 Examples of the continuing role of race in medical research are evident in studies documenting differences in the aggressiveness of treatment ordered for white patients and black patients with cancer 25 and heart disease. 26 Many of the methodologies are rightly criticized for their lack of rigidity. 27 Flaws in data collection do not explain entirely the conclusions, however. 28 To the extent that such disparities between the health status and medical treatment of persons in different ethnic groups exist, one must ask whether the goal of eliminating such disparities is better served by overlooking race as a legitimate factor in health status or by accepting its role not as a predictor of fundamental biological difference but as a partial measure of social environments that may affect the odds of successful treatment. Ethnicity may well become the preferred term in such contexts, but semantics are not likely to matter unless accompanied by an emphasis on the issues that underlie the discrepancies in health.
Similarly, where the elimination of ethnic disparities in health status may be linked with the availability of therapies that are best suited for persons with a genotypic characteristic that occurs with greater frequency in a group of persons roughly approximating a historical racial category, the question is whether the benefit of noting the rough approximation for any purpose outweighs the danger of perpetuating partially misleading or completely disproved perceptions of biological heterogeneity between racial classifications and homogeneity within racial classifications. As ever, the health care system will be charged with delivering a beneficial treatment to those who require medical care. Where pharmacogenomics leads to the production of drugs and diagnostic tests best suited for a genotype present in disproportionate numbers in groups of persons who are overrepresented among the socioeconomically disadvantaged, what role can pharmacogenomics play in the current health care system? Advances in pharmacogenomics will be funded in large part by pharmaceutical companies investing capital in new technologies so as to compete better in a profit-driven economy. The products of these endeavors will be no less expensive than the current selection of medications available by prescription and likely will be more costly. Will the current framework for delivering medical care absorb pharmacogenomics in a way that is meaningful for those persons who stand the greatest chance of benefit?
There is evidence that race is a factor www.nature.com/tpj in drug development strategies. 29 The development of drugs for one ethnic group over another could become more common as drug companies respond to the existence of relevant polymorphisms that may be more common to that group. This being the case, society must consider whether drug manufacturers should take an equitable approach in identifying and targeting markets in light of the politics of exclusion based on both race and wealth.
Too much of the wrong attention may prove equally harmful. A polymorphism appearing in a particular ethnic group may perpetuate social discrimination where the result is resistance to cheaper treatments for a given condition. This danger is not isolated to groups defined by their ethnicity, but an existing history of stigmatization based on ethnicity makes the danger seem more real.
Another question is whether a drug proven to serve a need particularly pressing to a certain population should be marketed to that group when the group identifier, race, is politically charged and arguably irrelevant as a predictor of beneficial use. If an ethnic group whose members identify themselves as part of that group share an increased risk for susceptibility to a disease or resistance to conventional drug therapy for a disease that occurs disproportionately in a group of that particular ethnicity, which is more harmful and to whom?: the reality that, increased risk notwithstanding, a racial group shares so little in common genetically that the term or label should be ignored entirely, or the perpetuation of race as an inaccurate but still effective shorthand for communicating information about disease susceptibility or a danger of toxic effects from a drug? Even where the relevant genetic variation is attributable to historical patterns of human migration and is not exclusively or even most accurately defined or predicted by skin color, race is likely to remain as a stand-in, however sloppy, until completely disproven and replaced with a newer, more effective term.
A FRAMEWORK FOR FUTURE PRACTICE
Pharmacogenomics is based on the identification of genetic variations that affect drug response in individuals and in population groups. Difference, not sameness, drives advances in drug discovery and development in pharmacogenomic research. Patterns of variation in drug response have led to the discovery of genetic variations that affect therapeutic strategies. The observation of different patterns of variation in drug response among groups of people is necessarily useful to the larger process. Observations of differences in responses to a drug in different groups that correspond with historical racial categories have been important to advances in pharmacogenomics. As an area of genetic research, pharmacogenomics is an example of the value that lies in acknowledging diversity in human genetics linked to population groups. In leading to the revelation of further patterns in genetic composition that form an accurate explanation for a legitimate difference, the acknowledgement of differences between loosely defined population groups will ultimately contribute to a mature understanding of the diversity between humans and the abandonment of race as a concept useful for any purpose.
The study of genetic diversity based on ethnic categories as a way toward the elimination of race in medical and law discourse is embodied by the Human Genome Diversity Project. This controversial attempt to capture the anthropological aspects of genetic diversity among population groups could be an important step in the acknowledgement of the complex meaning of difference in contemporary culture. Increasingly, race is a suspect concept for the classification of persons on either a biological or cultural level. Ethnicity is a more useful but still problematic concept in medical research. The resolution of the legitimate arguments over the use of such concepts will fade with time. Pharmacogenomics demonstrates the way in which human genetic diversity between ethnic groups could play the role of furtherance of medical research and particularly in genetic research. 
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